Director Buys $100K in Lantern Pharma Offering
LTRN has more than doubled off its 52-week low of $1.11 on elevated volume (2.0× avg).
Summary
A director of Lantern Pharma Inc. purchased over $100,000 worth of common stock in the company's recent offering, signaling insider confidence.
Key Events · Ownership and Investor Activity · LTRN
-
Director Participates in Offering
Director D. Jeffrey Keyser acquired 48,544 shares of common stock for $100,000.64 at a price of $2.06 per share on May 12, 2026.
-
Insider Confidence Signal
This open market purchase, representing 0.283% of the company's market cap, indicates a vote of confidence from a director following the recent capital raise.
-
Linked to Recent Offering
The shares were acquired as part of the company's offering that closed on May 14, 2026, which was announced on May 13 and finalized on May 14.
Analysis · LTRN · Life Sciences
Director D. Jeffrey Keyser's $100,001 purchase of common stock in Lantern Pharma's recent offering demonstrates insider confidence following the capital raise. This investment, made at the offering price, aligns the director's interests with shareholders after the company secured new funding, which is particularly notable given the company's prior 'going concern' warning.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTRN was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.4M. The 52-week trading range was $1.11 to $5.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.